Dare Bioscience, Inc. quarterly report, Q2 FY2015

Business context and reporting period

This is Cerulean Pharma Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015, filed August 6, 2015. The request identifies Dare Bioscience, Inc., but the filing itself is for Cerulean Pharma; the filing does not explain any relationship between the two companies. Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates. Its lead candidate, CRLX101, was in Phase 2 development, and CRLX301 was in Phase 1.

Financial results and key metrics

  • Revenue: None in Q2 or the first half of 2015. Comparatives were $33,000 for Q2 2014 and $80,000 for H1 2014, from research agreements that had ended.
  • Net loss: $9.9 million for Q2 2015 versus $7.4 million in Q2 2014; $18.3 million for H1 2015 versus $10.3 million in H1 2014. Basic and diluted loss per share was $0.37 for Q2 and $0.78 for H1 2015.
  • Operating expenses: Q2 research and development (R&D) was $6.7 million, up 152%; general and administrative (G&A) was $2.7 million, up 34%. H1 R&D was $11.7 million, up 182%; G&A was $5.4 million, up 53%. Most R&D was for CRLX101: $5.0 million in Q2 and $8.4 million in H1.
  • Cash flow: H1 operating cash use was $15.7 million, versus $7.9 million in H1 2014. Investing cash use was $0.3 million. Financing provided $50.4 million, and cash increased $34.3 million.
  • Cash and liquidity: Cash and cash equivalents were $85.5 million at June 30, 2015, compared with $51.2 million at year-end 2014. Management said cash was expected to fund operating expenses, debt service and capital expenditures into 2017, while cautioning that assumptions could prove wrong.
  • Debt: The company borrowed $15.0 million from Hercules in January 2015 and used part of the proceeds to repay its Lighthouse loan. The balance sheet reports $14.5 million of loan payable, plus $0.2 million of non-current accrued interest; MD&A describes approximately $16.1 million of outstanding Hercules indebtedness. The filing text does not clearly reconcile these amounts. The Hercules facility bears floating interest at a stated minimum of 7.30%, matures July 1, 2018, and is secured by substantially all assets except intellectual property.
  • Margins and profitability: Operating or gross margins are not meaningful because the company had no 2015 revenue. It reported an accumulated deficit of $140.1 million and had never been profitable.

Material changes versus the prior comparable period

Losses and operating cash use increased as the company expanded clinical development and corporate infrastructure. R&D growth reflected CRLX101 trial and clinical-site costs, increased headcount and manufacturing activity, alongside spending on CRLX301’s Phase 1 trial. G&A increased with public-company staffing, professional fees and insurance. H1 net loss rose 78%, although other expense was lower than in 2014 because the prior-year period included a $2.5 million loss on conversion of convertible notes. The 2015 financing included $37.2 million net proceeds from an April public offering; shares outstanding increased to 27.3 million at June 30, from 20.1 million at December 31, 2014.

Outlook, commentary, risks and unusual items

  • Management expected expenses and operating losses to increase as it advanced CRLX101 and CRLX301 and pursued additional research. It anticipated no product-sales revenue for several years, if ever, and said further capital would be needed to complete development and commercialization.
  • Clinical developments included FDA Orphan Drug designation for CRLX101 in ovarian cancer and Fast Track designation for CRLX101 plus Avastin in metastatic renal cell carcinoma (RCC). The company-sponsored Phase 2 RCC trial was enrolling, but site accrual had been slower than expected. A Phase 1b CRLX101/paclitaxel ovarian-cancer trial began during the quarter. CRLX301’s U.S. IND became effective in March 2015.
  • The filing notes that an earlier Phase 2 CRLX101 monotherapy trial in advanced non-small-cell lung cancer failed to meet its overall-survival primary endpoint. Trial enrollment, uncertain efficacy and safety, regulatory requirements, manufacturing dependence, competition, and the need for additional financing are prominent risks. Failure to raise capital could force the company to delay, reduce or end programs.
  • Additional Hercules loan tranches of up to $11.0 million were conditional on clinical and financing milestones; availability was not assured. Loan covenants and collateral could constrain future financing. Management’s runway estimate was not a guarantee.
  • Subsequent event: on July 9, 2015, Cerulean signed a lease for approximately 22,992 square feet in Waltham, Massachusetts, commencing December 28, 2015 and expiring February 28, 2021. Annual base rent for each of the first two years is $689,760, plus operating expenses, utilities and taxes; a $229,920 letter of credit was provided as security.
  • Management reported effective disclosure controls as of June 30, 2015 and no material change in internal control over financial reporting during the first half.

Important facts an investor should verify

  1. Confirm the issuer identity: this filing names Cerulean Pharma Inc., not Dare Bioscience, Inc.
  2. Reconcile the approximately $16.1 million debt amount in MD&A with the balance-sheet loan payable and accrued-interest figures, and review Hercules’ covenants, collateral and milestone conditions for further draws.
  3. Assess the basis and sensitivities behind management’s estimate that cash would fund operations into 2017, given H1 operating cash use of $15.7 million and expected rising expenses.
  4. Check current enrollment, trial results and timelines for CRLX101 and CRLX301, particularly the slower RCC enrollment and the prior CRLX101 trial failure.
  5. Review the full lease obligations and relocation costs, as well as the company’s dependence on future financing and potential dilution.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.